Limbic System Abnormalities Identified in Schizophrenia using Positron Emission Tomography with Fluorodeoxyglucose and Neocortical Alterations with Deficit Syndrome

Archives of General Psychiatry

Volumn 49, Issue 7, 1992, Pages 522-530

  Tamminga, Carol A ^a,b   Thaker, Gunvant K ^a,b   Buchanan, Robert ^a,b   Kirkpatrick, Brian ^a,b   Alphs, Larry D ^a,b   Chase, Thomas N ^a,b   Carpenter, William T ^a,b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; FLUORODEOXYGLUCOSE F 18; PHENCYCLIDINE;

ADOLESCENT; ADULT; ARTICLE; BASAL GANGLION; BRAIN METABOLISM; CLINICAL ARTICLE; CONTROLLED STUDY; EXTRAPYRAMIDAL SYSTEM; FEMALE; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HUMAN; LIMBIC SYSTEM; MALE; METABOLIC RATE; NEOCORTEX; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PSYCHOSIS; RATING SCALE; SCHIZOPHRENIA; THALAMUS;

ADOLESCENT; ADULT; CEREBRAL CORTEX; DEOXYGLUCOSE; EXTRAPYRAMIDAL TRACTS; FEMALE; FLUDEOXYGLUCOSE F 18; GLUCOSE; GYRUS CINGULI; HIPPOCAMPUS; HUMAN; LIMBIC SYSTEM; MALE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0026659790     PISSN: 0003990X     EISSN: 15383636     Source Type: Journal    
DOI: 10.1001/archpsyc.1992.01820070016003     Document Type: Article

References (78)

1. Jacobi W, Winkler H. Encephalographische Studien an Schizophrenen. Arch Psychiatr Nervenkr. 1928;84: 208–226.
2. Haug JO. Pneumoencephalographic studies in mental disease. Acta Psychiatr Scand. 1962;38(suppl): 1–104.
3. Johnstone EC, Crow TJ, Frith DC, Husband J, Kreel L. Cerebral ventricular size and cognitive impairment in schizophrenia. Lancet. 1976;2: 924–926.
4. Weinberger DR, Torrey EF, Neophytides AN, Wyatt RJ. Lateral ventricular enlargement in chronic schizophrenia. Arch Gen Psychiatry. 1979;36: 735–739.
5. Coffman JA, Nasrallah HA. Magnetic resonance brain imaging in schizophrenia. In: Nasrallah HA, Weinberger DR, eds. Handbook of Schizophrenia: The Neurology of Schizophrenia. New York, NY: Elsevier Science Publishing Co Inc; 1986;1: 50–69.
6. Weinberger DR, Wagner RL, Wyatt RJ. Neuropathological studies of schizophrenia: a selective review. Schizophr Bull. 1983;9: 193–212.
7. Ingvar DH, Franzen G. Abnormalities of cerebral blood flow distribution in patients with chronic schizophrenia. Acta Psychiatry Scand. 1971;50: 425–462.
8. Weinberger DR, Berman KF, Zee RF. Physiologic dysfunction of dorso-lateral prefrontal cortex in schizophrenia, I: regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43: 114–124.
9. Early TS, Reiman EM, Raichle ME, Spitznagel EL. Left globus pallidus abnormality in never-medicated patients with schizophrenia. Proc Natl Acad Sci USA. 1987;84: 561–563.
10. Buchsbaum MS, Nuechterlein KH, Haier RJ, Wu J, Sicotte N, Hazlett E, Asarnow R, Potkin S, Guich S. Glucose metabolic rate in normals and schizophrenics during the continuous performance test assessed by positron emission tomography. Br J Psychiatry. 1990; 156: 216–227.
11. Cleghorn JM, Kaplan RD, Nahmias C, Garnett ES, Szechtman H, Szechtman B. Inferior parietal region implicated in neurocognitive impairment in schizophrenia. Arch Gen Psychiatry. 1989;46: 758–760.
12. DeLisi LE, Buchsbaum MS, Holcomb HH, Langston KC, Kins AC, Kessler R, Pickar D, Carpenter WT, Morihisa JM, Margolin R. Increased temporal lobe glucose use in chronic schizophrenic patients. Biol Psychiatry. 1989;25: 835–851.
13. Wolkin A, Angrist B, Wolf A, Brodie JD, Wolkin B, Jaeger J, Cancro J, Rotrosen J. Low frontal glucose utilization in chronic schizophrenia: a replication study. Am J Psychiatry. 1988;145: 251–253.
14. Szechtman H, Nahmias C, Garnett S, Firnau G, Brown G, Kaplan R, Cleghorn J. Effect of neuroleptics on altered cerebral glucose metabolism in schizophrenia. Arch Gen Psychiatry. 1988;45: 523–532.
15. Volkow NS, Wolf AP, Gelder PV, Brodie JD, Overall JE, Cancro R, Gomez-Mont F. Phenomenological correlates of metabolic activity in 18 patients with chronic schizophrenia. Am J Psychiatry. 1987;144: 151–158.
16. Gur RE, Resnick SM, Alavi A, Gur RC, Caroff S, Dann R, Silver FL, Saykin AJ, Chawluk JB, Kushner M, Reivich M. Regional brain function in schizophrenia. Arch Gen Psychiatry. 1987;44: 119–125.
17. Cohen RM, Semple WE, Gross M, Nordahl TE, Holcomb HH, Dowling MS, Pickar D. The effect of neuroleptics on dysfunction in a prefrontal substrate of sustained attention in schizophrenia. Life Sci. 1988;43: 1141–1150.
18. Kling AS, Metter EJ, Reige WH, Kuhl DE. Comparison of PET measurement of local brain glucose metabolism and CAT measurement of brain atrophy in chronic schizophrenia and depression. Am J Psychiatry. 1986;143: 175–180.
19. Wiesel FA, Blomqvist G, Greitz T, Nyman H, Schalling D, Stone Elander S, Widen L, Wik G. Regional brain glucose metabolism in neuroleptic free schizophrenic patients in an acute phase of the disease. Acta Psychiatr Scand. 1987;76: 628–641.
20. Wolkin A, Jaeger J, Brodie JD, Wolf AP, Fowler J, Rotrosen J, Gomez-Mont F, Cancro R. Persistence of cerebral metabolic abnormalities in chronic schizophrenia as determined by positron emission tomography. Am J Psychiatry. 1985;142: 564–571.
21. DeLisi LE, Holcomb HH, Cohen RM, Pickar D, Carpenter W, Morihisa JM, King AC, Kessler R, Buchsbaum MS. Positron emission tomography in schizophrenic patients with and without neuroleptic medication. J Cereb Blood Flow Metab. 1985;5: 201–206.
22. Jernigan TL, Sargent T, Pfefferbaum A, Kusubov N, Stahl SM. 18Fluorodeoxyglucose PET in schizophrenia. Psychiatry Res. 1985;16: 317–329.
23. Buchsbaum MS, DeLisi LE, Holcomb HH, Cappelletti J, King AC, Johnson J, Hazlett E, Dowling-Zimmerman S, Post RM, Morihisa J, Carpenter W, Cohen R, Pickar D, Weinberger DR, Margolin R, Kessler RM. Anteroposterior gradients in cerebral glucose use in schizophrenia and affective disorders. Arch Gen Psychiatry. 1984;41: 1159–1166.
24. Farkas T, Wolf AP, Jaeger J, Brodie JD, Christman DR, Fowler JS. Regional brain glucose metabolism in chronic schizophrenia. Arch Gen Psychiatry. 1984;41: 293–300.
25. Buchsbaum MS, Ingvar DH, Kessler R, Waters RN, Cappelletti J, van Kammen DP, King AC, Johnson JL, Manning RG, Flynn RW, Mann LS, Bunney WE, Sokoloff L. Cerebral glucography with positron tomography. Arch Gen Psychiatry. 1982;39: 251–259.
26. Sokoloff L, Reivich M, Kennedy C, Des Rosiers MH, Patlak CS, Pettigrew KD, Sakurada O, Shinohara M. The (14C)-deoxyglucose method for measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem. 1977;28: 897–916.
27. Reivich M, Kuhl D, Wolf A, Greenberg J, Phelphs M, Ido T, Cascella V, Fowler J, Hoffman E, Alavi A, Som P, Sokoloff L. The (18F) fluorodeoxyglucose method for the measurement of local cerebral glucose utilization in man. Circ Res. 1979;44: 127–137.
28. Kadekaro M, Vance WH, Terrell ML, Gary H, Eisenberg HM, Sokoloff L. Effects of antidromic stimulation of the ventral root on glucose utilization in the ventral horn of the spinal cord in the rat. Proc Natl Acad Sci USA. 1987;84: 5492–5495.
29. Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelly R. Study of a new schizophrenomimetic drug: serenyl. Arch Neurol Psychiatry. 1959;71: 363–369.
30. Rosenbaum G, Cohen BD, Luby E, Gottlieb JS, Yelen D. Comparison of serenyl with other drugs: simulation of schizophrenia performance with serenyl, LSD-25, and amylbarbital (Amytal) sodium. Arch Gen Psychiatry. 1959;1: 113–118.
31. Pearlson GD. Psychiatric and medical syndromes with phencyclidine (PCP) abuse. Johns Hopkins Med J. 1981;148: 25–33.
32. Tamminga CA, Tanimoto K, Kuo S, Chase TN, Contreras PC, Rice KC, Jackson AE, O'Donohue TL. PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by Metaphit, a PCP-receptoracylating agent. Synapse. 1987;1: 497–504.
33. Nehls DG, Kurumaji A, Park CK, McCulloch J. Differential effects of competitive and non-competitive N-methyl-D-aspartate antagonists on glucose use in the limbic system. Neurosci Lett. 1988;91: 204–210.
34. Weissman AD, Dam M, London ED. Alterations in local cerebral glucose utilization induced by phencyclidine. Brain Res. 1987;435: 29–40.
35. Gao XM, Shirakawa O, Tamminga CA. Delayed phencyclidineinduced alterations in local cerebral glucose utilization in rat brain. Neurosci Abs. 1991;575:1453.
36. Wing JK, Cooper JE, Sartorius H. Measurement and Classification of Psychiatric Symptoms. London, England: Cambridge University Press; 1974.
37. Schooler NR, Kane JM. Research diagnosis for tardive dyskinesia. Am J Psychiatry. 1982;39: 486–487.
38. Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. Psychol Rep. 1962;10: 799–812.
39. Smith RC, Strizich M, Klass D. History of neuroleptic drugs and tardive dyskinesia. In: Fann WE, Smith RC, Davis JM, Domino EF, eds. Tardive Dyskinesia: Research and Treatment. New York, NY: SP Medical & Scientific Books; 1980: 152–158.
40. Kirkpatrick B, Buchanan RW, McKenney PD, Alphs LD, Carpenter WT. The Schedule for the Deficit Syndrome: an instrument for research in schizophrenia. Psychiatry Res. 1989;30: 119–123.
41. Brooks RA, Friant WS, Sank VS, Cascro HE, Leighton SB, DiChiro G. Initiated evaluation of a high resolution positron emission tomograph. In: Greitz T, ed. The Metabolism of the Human Brain Studied With Positron Emission Tomography. New York, NY: Raven Press; 1985: 57–68.
42. DiChiro G, Brooks RA, Patronas NJ, Bairamian D, Kornblith PL, Smith BH, Mansi L, Barker J. Issues in the in vivo measurement of glucose metabolism of human central nervous system tumors. Ann Neurol. 1984;15: 138–146.
43. Phelps ME, Huang SC, Hoffman EJ, Selin C, Sokoloff L, Kuhl DE. Tomographic measurement of local cerebral glucose metabolic rates in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol. 1979;6: 371–388.
44. Reivich M, Alava A, Wolf AP, Fowler J, Russell J, Arnett C, MacGregor RR, Shiue CY, Atkins H, Anaud A, Dahn R, Greenberg JH. Glucose metabolic rate kinetic model parameter determination in man: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose. J Cereb Blood Flow Metab. 1985;5: 179–192.
45. Brooks RA, Hatazawa J, DiChiro G, Larson SM, Fishbein DS. Human cerebral glucose metabolism determined by positron emission tomography: a revisit. J Cereb Blood Flow Metab. 1987;7: 427–432.
46. Aquilonius SM, Eckernas SA. A Colour Atlas of the Human Brain: Adapted to Computed Tomography. New York, NY: Raven Press;1980.
47. Nordah T, Valk P, Cummings A, Jusubov N, Jagust W, Huesman R, Budinger T. Hippocampal glucose metabolism in schizophrenia. Biol Psychiatry. 1991;20(suppl):333. Abstract.
48. Gruzelier J, Seymour K, Wilson L, Jolley A, Hirsch S. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry. 1988;45: 623–629.
49. Gruzelier JH. Bimodal states of arousal and lateralized dysfunction in schizophrenia: the effect of chlorpromazine. In: Wynne L, Cromwell R, Matthysse S, eds. The Nature of Schizophrenia: New Approaches to Research and Treatment. New York, NY: John Wiley & Sons Inc; 1978: 167–187.
50. Gruzelier JH. Schizophrenia central nervous system signs. In: Frederiks JAM, ed. Handbook of Clinical Neurology: Neurobehavioural Disorders. Amsterdam, the Netherlands: Elsevier Science Publishers; 1979;2: 481–521.
51. Squire LR. Memory and Brain. New York, NY: Oxford University Press Inc; 1987.
52. Eichenbaum H, Wiener SI, Shapiro ML, Cohen NJ. The organization of spatial coding in the hippocampus: a study of neural ensemble activity. J Neurosci. 1989;9: 2764–2775.
53. Olton DS, Wible CG, Shapiro ML. Mnemonic theories of hippocampal function. Behav Neurosci. 1986;100: 852–857.
54. MacLean PD. An ongoing analysis of hippocampal inputs and outputs: microelectrode and neuroanatomical findings in squirrel monkeys. In: Isaacson RI, Pribram KH, eds. The Hippocampus. New York, NY: Plenum Press; 1975;1: 63–69.
55. Bischoff S. Mesohippocampal dopamine system: characterization, functional and clinical implications. In: Isaacson RI, Pribram KH, eds. The Hippocampus. New York, NY: Plenum Publishing Corp; 1986;3: 179–184.
56. Scheibel AB, Kovelman JA. Disorientation of the hippocampal pyramidal cell and its processes in schizophrenia patients. Biol Psychiatry. 1981;16: 101–102.
57. Kovelman JA, Scheibel AB. A neurohistological correlate of schizophrenia. Biol Psychiatry. 1984;19: 1601–1619.
58. Altshuler LL, Conrad A, Kovelman JA, Scheibel A. Hippocampal pyramidal cell orientation in schizophrenia. Arch Gen Psychiatry. 1987;44: 1094–1098.
59. Christison GW, Casanova MF, Weinberger DR, Rawlings R, Kleinman JE. A quantitative investigation of hippocampal pyramidal cell size, shape, and variability of orientation in schizophrenia. Arch Gen Psychiatry. 1989;46: 1027–1032.
60. Jakob H, Beckman H. Prenatal developmental disturbances in the limbic allocortex in schizophrenics. J Neural Transm. 1986;65: 303–326.
61. Pakkenberg B. Pronounced reduction of total neuron number in mediodorsal thalamic nucleus and nucleus accumbens in schizophrenics. Arch Gen Psychiatry. 1990;47: 1023–1027.
62. Benes FM, Bird ED. An analysis of the arrangement of neurons in the cingulate cortex of schizophrenic patients. Arch Gen Psychiatry. 1987;44: 608–616.
63. Benes FM. Myelination of cortical-hippocampal relays during late adolescence. Schizophr Bull. 1989;15: 585–593.
64. Bogerts B, Meertz E, Schonfeldt-Bausch R. Basal ganglia and schizophrenia. Arch Gen Psychiatry. 1985;42: 784–791.
65. Falkai P, Bogerts B. Cell loss in the hippocampus of schizophrenics. Eur Arch Psychiatry Neurol Sci. 1986;236: 154–161.
66. Jeste DV, Lohr JB. Hippocampal pathologic findings in schizophrenia. Arch Gen Psychiatry. 1989;46: 1019–1026.
67. Suddath RL, Casanova MF, Goldberg TE. Temporal lobe pathology in schizophrenia: a quantitative magnetic resonance imaging study. Am J Psychiatry. 1989;146: 464–472.
68. Suddath RL, Christison GW, Torrey EF, Casanova MF, Weinberger DR. Anatomical abnormalities in the brains of monozygotic twins discordant for schizophrenia. N Engl J Med. 1990;322: 789–794.
69. Colter N, Battal S, Crow TJ. White matter reduction in the parahippocampal gyrus of patients with schizophrenia. Arch Gen Psychiatry. 1987;44:1023.
70. Bogerts B, Ashtari M, Degreef G, Alvir JM, Bilder RM, Lieberman JA. Reduced temporal limbic structure volumes on magnetic resonance images in first episode schizophrenia. Psychiatry Res. 1990;35: 1–13.
71. Stevens JR. An anatomy of schizophrenia? Arch Gen Psychiatry. 1973;29: 177–189.
72. Buchanan RW, Kirkpatrick B, Heinrichs DW, Carpenter WT. Clinical correlates of the deficit syndrome of schizophrenia. Am J Psychiatry. 1990;3: 290–292.
73. Thaker GK, Nguyen JA, Tamminga CA. Saccadic distractibility in schizophrenic patients with tardive dyskinesia. Arch Gen Psychiatry. 1989;46: 755–756.
74. Carpenter WT, Kirkpatrick B, Buchanan RW, Thakerr GK, Tamminga CA. The validity of the deficit syndrome. Schizophr Res. 1991;4: 251–252.
75. Papez JW. A proposed mechanism of emotion. Arch Neurol Psychiatry. 1937;38: 725–743.
76. Alexander GE, Crutcher MD, DeLong MR. Basal gangliathalamocortical circuits: parallel substrates for motor, oculomotor, ‘prefrontal’ and ‘limbic’ functions. Prog Brain Res. In press.
77. Bischoff S, Christen P, Vassout A. Blockade of hippocampal dopamine (DA) receptors: a tool for antipsychotics with low extrapyramidal side effects. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12: 455–467.
78. Lewis SW, Owen MJ, Murray RM. Obstetric complications and schizophrenia: methodology and mechanisms. In: Schulz SC, Tamminga CA, eds. Schizophrenia: Scientific Progress. New York, NY: Oxford University Press; 1989;6: 56–68.